A biomarker for predicting NSCLC radiotherapy resistance and its application

By using Fibulin-5 as a biomarker, its expression level in NSCLC tumor tissue was detected, the problem of lack of specific markers in the prior art was solved, and the prediction and reversal of NSCLC radiotherapy resistance was achieved, and the efficacy of radiotherapy was improved. Accuracy of prognostic evaluation.

CN118243926BActive Publication Date: 2024-12-03SHANDONG RES INST OF TUMOUR PREVENTION TREATMENT
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410448848.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-15
Publication Date
2024-12-03
Estimated Expiration
2044-04-15

AI Technical Summary

Technical Problem

The prior art lacks specific biomarkers for predicting non-small cell lung cancer (NSCLC) radiotherapy resistance, resulting in difficulty in predicting and prognosis evaluation of radiotherapy efficacy and affecting therapeutic effects.

Method used

Using Fibulin-5 as a biomarker for predicting NSCLC radiotherapy resistance, by detecting its expression level in tumor tissues, provides kits for specific antibody binding and drugs that inhibit Fibulin-5 expression to predict and reverse radiotherapy resistance.

Benefits of technology

Through bioinformatics technology screening and tissue immunohistochemistry verification, it was confirmed that the high expression of Fibulin-5 is related to the adverse prognosis of NSCLC patients, which can predict the efficacy of radiotherapy, and can also reduce tumor growth and increase radiotherapy sensitivity by inhibiting Fibulin-5 expression and improve NSCLC. Effects of radiotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118243926B_ABST
    Figure CN118243926B_ABST
Patent Text Reader

Abstract

The present invention discloses a biomarker for predicting radiotherapy resistance of NSCLC and its application, and relates to the field of biomedicine technology. The biomarker is Fibulin-5. The present invention screens out the high expression of Fibulin-5 in radiotherapy-resistant NSCLC through bioinformatics technology, and proves that Fibulin-5 expression is associated with poor prognosis of NSCLC patients through tissue immunohistochemistry, and can predict the efficacy of radiotherapy. In vivo and in vitro experiments have confirmed that inhibiting Fibulin-5 expression can slow tumor growth and increase radiotherapy sensitivity. At the same time, it has also been confirmed that Fibulin-5 inhibits ferroptosis by regulating the Src-STAT3-ACSL4 axis, thereby enhancing the radiotherapy resistance of NSCLC. The present invention has important clinical application value for the prediction of radiotherapy resistance and radiotherapy efficacy of NSCLC, prognosis evaluation, and improvement of the efficacy of radiotherapy-resistant NSCLC.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to a biomarker for predicting NSCLC radiotherapy resistance and an application thereof. Background Art

[0002] Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all newly diagnosed lung cancer cases and is the leading cause of cancer-related deaths worldwide. Radiotherapy plays an important role in the radical and palliative treatment of NSCLC, but current clinical case studies have found that some patients do not achieve good results after radiotherapy, and the tumor does not shrink, and even grows after a period of time, leading to rapid deterioration of the disease. These manifestations all indicate that radiotherapy resistance has occurred after radiotherapy. The reason is that during radiotherapy, tumor cells that cannot tolerate radiotherapy rays are killed, while tumor cells that can tolerate radiotherapy rays survive, and after a period of time, these cells will continue to multiply and metastasize. Recurrence and metastasis caused by radiotherapy resistance is still the main factor leading to treatment failure.

[0003] Biomarkers refer to biochemical indicators that can mark changes or possible changes in the structure or function of systems, organs, tissues, cells and subcellular structures. They have a wide range of uses and can be used for disease diagnosis, disease staging, efficacy prediction and prognosis assessment. Currently, NSCLC lacks specific radiotherapy resistance biomarkers. Therefore, in clinical treatment, it is urgent to discover such reliable biomarkers to better serve the radiotherapy of NSCLC. Summary of the invention

[0004] The purpose of the present invention is to provide a biomarker for predicting NSCLC radiotherapy resistance and its application to solve the problems existing in the above-mentioned prior art. The biomarker can be used to predict NSCLC radiotherapy resistance, which has important clinical application value for predicting radiotherapy resistance and radiotherapy efficacy of NSCLC, prognosis evaluation, and improving the efficacy of radiotherapy-resistant NSCLC.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] The present invention provides a biomarker for predicting NSCLC radiotherapy resistance, wherein the biomarker is Fibulin-5.

[0007] Furthermore, the higher the expression level of Fibulin-5 in the tumor tissue of NSCLC patients, the worse the therapeutic effect of radiotherapy for the NSCLC patients.

[0008] The present invention also provides the use of a reagent for detecting the expression level of the above-mentioned biomarker in tumor tissue of NSCLC patients in preparing a kit for predicting NSCLC radiotherapy resistance.

[0009] Furthermore, the reagent includes an antibody that specifically binds to the biomarker.

[0010] Furthermore, the antibody is a monoclonal or polyclonal antibody.

[0011] The present invention also provides a kit for predicting NSCLC radiotherapy resistance, comprising a reagent for detecting the expression level of the above-mentioned biomarkers in tumor tissues of NSCLC patients.

[0012] Furthermore, the reagent includes an antibody that specifically binds to the biomarker.

[0013] Furthermore, the antibody is a monoclonal or polyclonal antibody.

[0014] The present invention also provides the use of a reagent for inhibiting the expression level of the above-mentioned biomarker in tumor tissue of NSCLC patients in the preparation of a drug for reversing NSCLC radiotherapy resistance.

[0015] The present invention also provides a drug for reversing NSCLC radiotherapy resistance, comprising an agent for inhibiting the expression level of the above-mentioned biomarkers in tumor tissues of NSCLC patients.

[0016] The present invention discloses the following technical effects:

[0017] The present invention screened out Fibulin-5 through bioinformatics technology and found that it is highly expressed in radiotherapy-resistant NSCLC, and proved that Fibulin-5 expression is related to the poor prognosis of NSCLC patients through tissue immunohistochemistry, and can predict the efficacy of radiotherapy. In vivo and in vitro experiments confirmed that Fibulin-5 is highly expressed in radiotherapy-resistant cell lines, and tumor growth can be slowed down and radiotherapy sensitivity can be increased by inhibiting Fibulin-5 expression. At the same time, it was also confirmed that Fibulin-5 inhibits ferroptosis by regulating the Src-STAT3-ACSL4 axis, thereby enhancing NSCLC radiotherapy resistance. The present invention has important clinical application value for the prediction of radiotherapy resistance and radiotherapy efficacy of NSCLC, prognosis evaluation, and improvement of the efficacy of radiotherapy-resistant NSCLC. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0019] Figure 1This is the expression analysis chart of Fibulin-5 protein level in various human tissues from the Human Protein Atlas website;

[0020] Figure 2 This is the survival analysis diagram of the FBLN5 high expression group and low expression group in the TCGA database;

[0021] Figure 3 This is the correlation analysis diagram between FBLN5 expression and various cancer grades of NSCLC in the TCGA database;

[0022] Figure 4 This is a statistical chart of the detection results of Fibulin-5 protein expression levels in the CR group and the NCR group in the clinical validation experiment of Example 2;

[0023] Figure 5 The receiver operating characteristic curve for Fibulin-5 was used to predict the efficacy of radiotherapy;

[0024] Figure 6 This is a Cox-PFS survival analysis diagram of the Fibulin-5 high expression and low expression groups in the clinical validation experiment of Example 2;

[0025] Figure 7 The results of knocking down FBLN5 in human lung CAFs and co-culturing with A549 and then radiotherapy to detect the protein expression level of DNA damage marker γH2AX;

[0026] Figure 8 Results of knocking down FBLN5 in mouse fibroblasts NIH-3T3 and co-culturing with LLC and then radiotherapy to detect the protein expression level of DNA damage marker γH2AX;

[0027] Fig. 9 A549 cells were cultured alone or co-cultured with CAFs that knocked down or overexpressed FBLN5, then irradiated with 12 Gy, and cell apoptosis was detected by flow cytometry;

[0028] Fig.10 A549 cells were cultured alone or co-cultured with CAFs that knocked down or overexpressed FBLN5, then irradiated with 12 Gy, and the cell cycle was detected by flow cytometry;

[0029] Fig.11 The results of protein level detection of molecules related to the Src-STAT3-ACSL4 pathway axis in fibroblasts (NIH-3T3 and CAFs) with knockdown or overexpression of FBLN5;

[0030] Fig.12The results of protein level detection of Src-STAT3-ACSL4 axis-related molecules in cancer cells after co-culture of fibroblasts (NIH-3T3 and CAFs) with knockdown or overexpression of FBLN5 with cancer cells (A549 and LLC);

[0031] Fig.13 Tumor growth curves of nude mice injected subcutaneously with cancer cell A549 alone, mixed with fibroblasts CAF, or mixed with FBLN5 knockdown fibroblasts (CAF);

[0032] Fig.14 Cancer cell A549 was injected subcutaneously into nude mice alone, mixed with fibroblasts CAF, or mixed with fibroblasts (CAF) with knockdown of FBLN5. The growth curve of the tumor after a single radiotherapy of 15 Gy was obtained. DETAILED DESCRIPTION

[0033] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0034] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0035] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0036] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0037] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0038] Terminology Note:

[0039] Fibulin-5 in the present invention, also known as FBLN5 or DANCE, and its Chinese name is key aging protein 5, is a 66-KD secretory glycoprotein secreted by tumor-associated fibroblasts (CAFs) in the NSCLC microenvironment.

[0040] Example 1 Bioinformatics Analysis of Radiotherapy Resistance Markers

[0041] Analysis of the Human Protein Atlas website showed that Fibulin-5 expression was higher in lung tissue compared with other tissues ( Figure 1 ).

[0042] Analysis of the TCGA database showed that high expression of Fibulin-5 predicted poor prognosis in lung adenocarcinoma and lung squamous cell carcinoma, and Fibulin-5 expression was positively correlated with NSCLC cancer stage (e.g. Figure 2 and Figure 3 ).

[0043] Example 2 Clinical Validation of Radiotherapy Resistance Markers

[0044] By performing immunohistochemical staining in clinical puncture tissue samples of NSCLC and combining the patient's clinical information, the role of Fibulin-5 expression level in predicting the patient's radiotherapy efficacy and prognosis evaluation was verified.

[0045] Methods: Tumor biopsy tissue samples from 65 NSCLC patients who underwent radiotherapy were included. Patients' tumor tissues were sent to Servicebio for fixation, paraffin embedding, and serial sectioning. After deparaffinization, antigen removal, and blocking, the sections were incubated with primary antibodies at 4°C overnight. They were then stained with DAB and counterstained with hematoxylin. When evaluating Fibulin-5 immunostaining, tissue microarrays were independently examined by two pathologists using a light microscope. Positive cells in each 1 mm diameter area were counted using Image-pro Plus 6.0 software (MediaCybernetics Inc.) and expressed as the average of three replicates.

[0046] In order to clarify the predictive efficacy of Fibulin-5 on the efficacy of radiotherapy for NSCLC, NSCLC patients were divided into CR (complete disappearance of tumor lesions after radiotherapy) and non-CR group (NCR) according to the clinical efficacy evaluation index of solid tumors. The expression level of Fibulin-5 in the NCR group was significantly higher than that in the CR group ( Figure 4 ).

[0047] The receiver operating characteristic curve analysis was performed in combination with the expression level of Fibulin-5. The results showed that Fibulin-5 had a high efficacy in predicting efficacy, with an AUC value of 0.801 and a cut-off value of 45 ( Figure 5 ).

[0048] According to the average expression of Fibulin-5, NSCLC patients were divided into Fibulin-5 high expression and low expression groups, and then Cox-PFS survival analysis was performed. The results showed that increased Fibulin-5 expression was associated with low progression-free survival (PFS) and advanced clinical stage in NSCLC patients ( Figure 6 ).

[0049] Example 3 In vitro validation of radiotherapy resistance markers

[0050] Western blotting, lentiviral transfection to construct stable knockdown gene cell line experiments, apoptosis detection experiments and cell cycle experiments proved that high expression of Fibulin-5 is associated with radiotherapy resistance of NSCLC cells ( Figure 7-10 ).

[0051] Western blotting:

[0052] Total proteins from fibroblasts and NSCLC cells were extracted using RIPA lysis buffer. Protein concentration was determined using the BCA method. Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes. The membranes were incubated with primary antibodies overnight at 4°C and then detected using horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) and enhanced chemiluminescence (Pierce).

[0053] Lentiviral transfection to construct stable knockdown gene cell line experiment:

[0054] In order to stably knock down the FBLN5 gene, the shRNA lentivirus was transfected into the fibroblast cell line, and puromycin (1 μg / mL) was used to select positive cells with stable knockdown of FBLN5 within one week.

[0055] Apoptosis detection experiment:

[0056] NSCLC cells were cultured in six-well plates and pretreated with CM from fibroblasts for 48 h. The treated NSCLC cells were irradiated, and 72 h later, the cells were washed with PBS, harvested using EDTA-free trypsin, stained with Annexin V-FITC apoptosis detection kit (BD Biosciences), and analyzed by flow cytometry (FCM).

[0057] Cell cycle assay:

[0058] Cell cycle analysis was performed using a cell cycle analysis kit (Beyotime, China) according to the manufacturer's instructions. A549 cells were dissociated with trypsin, centrifuged at 1000 rpm for 5 minutes, and then fixed with 70% ethanol and stored at -20°C overnight. Before flow cytometry, cells were stained with PI staining solution at room temperature for 30 minutes.

[0059] After knocking down the FBLN5 gene in human lung CAF, they were co-cultured with A549. After co-culture, A549 was radiotherapy-treated, and then the protein expression level of DNA damage marker γH2AX was detected. The results are shown in Figure 7 The results showed that knocking down the FBLN5 gene in CAFs could increase the protein expression level of γH2AX in A549 after radiotherapy.

[0060] Mouse fibroblasts NIH-3T3 were knocked down for FBLN5 gene and co-cultured with mouse Lewis lung cancer cells (LLC). After co-culture, LLC were radiotherapy, and then the expression level of DNA damage marker γH2AX protein was detected. The results are shown in Figure 8 The results showed that knocking down the FBLN5 gene with NIH-3T3 could increase the protein expression level of γH2AX in LLC after radiotherapy.

[0061] After knocking down or overexpressing the FBLN5 gene, CAFs were co-cultured with A549. After radiotherapy, apoptosis and cell cycle detection experiments were performed on A549. The results are shown in Figure 9-10 The results showed that after CAF knocked down the FBLN5 gene, the apoptosis rate of A549 cells after radiotherapy increased, and the proportion of cells in the G2 / M phase of the cell cycle increased; on the contrary, after CAF overexpressed the FBLN5 gene, the apoptosis rate of A549 cells after radiotherapy decreased, and the proportion of cells in the G2 / M phase of the cell cycle decreased.

[0062] Example 4 Mechanism of action of radiotherapy resistance markers

[0063] Lentivirus transfection to construct stable knockdown gene cell line experiments and Western blot experiments demonstrated that Fibulin-5 mediates ferroptosis by regulating the Src-STAT3-ACSL4 axis, thereby enhancing NSCLC radioresistance ( Figure 11-12 ).

[0064] Lentiviral transfection to construct stable knockdown gene cell line experiment:

[0065] In order to stably knock down the FBLN5 gene, the cells were infected with shRNA lentivirus (shRNA sequence 1: GCTGACATCTTCCAAATGCAA; shRNA sequence 2: CGAGGAGACATGATGTGTGTT), and puromycin (1 μg / mL) was used to select positive cells with stable knockdown of the FBLN5 gene within one week.

[0066] Western blotting:

[0067] Total proteins from fibroblasts and NSCLC cells were extracted using RIPA lysis buffer. Protein concentration was determined using the BCA method. Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes. The membranes were incubated with primary antibodies overnight at 4°C and then detected using horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) and enhanced chemiluminescence (Pierce).

[0068] Transmission Electron Microscopy:

[0069] Morphological features of ferroptosis examined using transmission electron microscopy include rupture of the mitochondrial outer membrane and reduced or absent mitochondrial cristae.

[0070] The results of protein level detection of Src-STAT3-ACSL4 axis-related molecules in fibroblasts and cancer cells with knockdown and overexpression of FBLN5 gene are shown in Figure 11-12 , the results showed that Fibulin-5 mediated ferroptosis by regulating the Src-STAT3-ACSL4 axis, thereby enhancing NSCLC radioresistance.

[0071] Example 5 In vivo verification of radiotherapy resistance markers

[0072] Animal Experimentation:

[0073] All animal handling procedures strictly followed the protocols approved by the Animal Care and Use Committee of the Affiliated Tumor Hospital of Shandong First Medical University (Jinan). 5-week-old female BALB / c nude mice were purchased from Beijing Life Experiment Animal Technology Center. Xenograft tumors in BALB / c nude mice were established by subcutaneous injection of two types of cells (i.e., A549 cancer cells and fibroblasts CAF or FBLN5 knockdown fibroblasts CAF-shFBLN5) or one type of cell (A549 cancer cells) into the right hind limb. The injection dose of A549 cancer cells was 1×10 7 The injection dose of fibroblasts CAF or FBLN5 knockdown fibroblasts CAF-shFBLN5 was 2×10 7 / ; the total injection volume of one or two cells was 200 μl.

[0074] Tumor size was measured weekly with a vernier caliper and the formula V = (length × width 2 ) / 2 to calculate the tumor volume. When the average tumor volume reaches about 100 mm 3 The tumor was treated with a single 15 Gy irradiation (IR) at 4 °C. The tumor size was then measured every two days until the tumor volume approached 1500 mm 3 After euthanasia, tumors were photographed and weighed.

[0075] The results of the mouse subcutaneous transplant tumor experiment showed that knocking down FBLN5 in CAFs could slow the growth of subcutaneous tumors in nude mice, proving that inhibiting FBLN5 gene expression can enhance radiosensitivity and inhibit tumor growth after radiotherapy ( Figure 13-14 ).

[0076] In summary, the present invention screened out Fibulin-5 in radiotherapy-resistant NSCLC through bioinformatics technology, and proved that Fibulin-5 expression was associated with poor prognosis of NSCLC patients through tissue immunohistochemistry, and could predict the efficacy of radiotherapy. In vitro and in vivo experiments confirmed that Fibulin-5 was highly expressed in radiotherapy-resistant cell lines, and tumor growth could be slowed down and radiotherapy sensitivity could be increased by inhibiting Fibulin-5 expression. It was also confirmed that Fibulin-5 inhibited ferroptosis by regulating the Src-STAT3-ACSL4 axis, thereby enhancing NSCLC radiotherapy resistance. The present invention has important clinical application value for the prediction of radiotherapy resistance and radiotherapy efficacy of NSCLC, prognosis evaluation, and improvement of radiotherapy-resistant NSCLC efficacy.

[0077] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Use of a reagent for detecting the expression level of a biomarker in tumor tissue of a NSCLC patient in the preparation of a kit for predicting NSCLC radiotherapy resistance, characterized in that: The biomarker is Fibulin-5; The higher the expression level of Fibulin-5 in the tumor tissue of NSCLC patients, the worse the therapeutic effect of radiotherapy for the NSCLC patients.

2. The use according to claim 1, characterized in that: The reagent includes an antibody that specifically binds to the biomarker.

3. The use according to claim 2, characterized in that: The antibody is a monoclonal or polyclonal antibody.

4. Use of a reagent for inhibiting the expression level of a biomarker in tumor tissue of a NSCLC patient in the preparation of a drug for reversing NSCLC radiotherapy resistance, characterized in that: The biomarker is Fibulin-5; The reagent is shRNA; The target sequence of the shRNA is shRNA sequence 1 or shRNA sequence 2; the shRNA sequence 1 is: GCTGACATCTTCCAAATGCAA; the shRNA sequence 2 is: CGAGGAGACATGATGTGTGTT.

Citation Information

Patent Citations

  • Marker and probe composition for screening lung adenocarcinoma and application of marker and probe composition

    CN116926191A